Zynerba Pharmaceuticals

Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE

DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) has provided program updates for Fragile X syndrome (FXS), autism spectrum disorder (ASD), 22q11.2 deletion syndrome (22q) and developmental and epileptic encephalopathies …

Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE Read More

Zynerba Pharmaceuticals

Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel in Fragile X Syndrome

DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) announced the initiation of a pivotal, multinational randomized, double-blind, placebo-controlled, multiple-center, efficacy and safety (RECONNECT) Phase 3 trial.

Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel in Fragile X Syndrome Read More